OMRI
Stancic replaces Michael Burshtine, who resigned in April (personal reasons: The presence of the CFO was required in
the U.S. full time. Burshtine is based in Israel, Relocation was the main issue).
They believe a head start to market for JNJ (from 1-4 months) will enable JNJ to more easily convert accounts from King's Thrombin JMI product to OMRI's and will better position JNJ for when ZGEN eventually does reach market, as JNJ will probably by then have a second FDA approval for a combined kit containing OMRI's Thrombin and JNJ's own Surgifoam absorbable sponge, positioning JNJ with three OMRI-related product offerings into wound care.
And before you say anything: yes, I do think that in time recombinants will take over the market (Endless supply free of blood donation, quality control much better, no fear of unknown diseases etc.).
Idit
